SPBPB21E7.05 Antibody

What is the SPBPB21E7.05 antibody and what organism does it target?

The SPBPB21E7.05 antibody is a polyclonal antibody specifically raised against the SPBPB21E7.05 protein from Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast . This antibody is developed using recombinant SPBPB21E7.05 protein as the immunogen and is produced in rabbits through established immunization protocols . The antibody targets a specific protein (Uniprot No. Q8NIL4) within the S. pombe proteome and has been affinity-purified to enhance its specificity . Understanding the target organism is crucial for experimental design as this antibody has been specifically validated for S. pombe studies and may not show cross-reactivity with proteins from other species without explicit validation.

What are the validated experimental applications for the SPBPB21E7.05 antibody?

The SPBPB21E7.05 antibody has been specifically validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blotting (WB) applications, making it suitable for protein detection and quantification in these common laboratory techniques . For Western blotting applications, this antibody can be used to detect the native or denatured target protein from S. pombe samples, providing a tool for investigating protein expression levels or post-translational modifications . In ELISA applications, the antibody enables quantitative detection of the target protein in solution phase assays . Researchers should note that when designing experiments with this antibody, proper controls should be implemented to ensure accurate antigen identification, as suggested by the manufacturer's recommendation to "ensure identification of antigen" . Applications beyond those explicitly tested would require validation by the researcher before proceeding with full experimental implementation.

How should the SPBPB21E7.05 antibody be properly stored and handled to maintain its efficacy?

Proper storage and handling of the SPBPB21E7.05 antibody is critical to maintaining its efficacy for experimental applications over time. Upon receipt, the antibody should be stored at either -20°C or -80°C, with the latter temperature potentially offering better long-term stability for extended storage periods . Repeated freeze-thaw cycles should be strictly avoided as they can lead to protein denaturation, aggregation, and loss of antibody functionality . The antibody is supplied in a stabilizing liquid formulation containing 50% glycerol, 0.01M PBS at pH 7.4, and 0.03% Proclin 300 as a preservative . This formulation helps maintain antibody integrity during storage . When working with the antibody, researchers should aliquot the stock solution into smaller volumes upon first thaw to minimize freeze-thaw cycles, and ensure all handling is done using sterile techniques to prevent microbial contamination that could degrade the antibody or introduce experimental artifacts.

What control samples should be included when using SPBPB21E7.05 antibody in Western blotting experiments?

When designing Western blotting experiments with the SPBPB21E7.05 antibody, a comprehensive set of controls is essential for result validation and troubleshooting. Researchers should include a positive control consisting of purified recombinant SPBPB21E7.05 protein or lysate from wild-type S. pombe known to express the target protein . A negative control using samples from SPBPB21E7.05 knockout strains (if available) is crucial to confirm antibody specificity . To account for potential cross-reactivity, include lysates from closely related yeast species to verify the antibody's species specificity . For method validation, incorporate a secondary antibody-only control (omitting primary antibody) to identify any non-specific binding from the secondary detection system . Additionally, a blocking peptide competition assay using the immunogenic peptide can effectively demonstrate epitope-specific binding, similar to the validation approach described for other antibodies in the literature . These controls collectively enable researchers to confidently interpret Western blot results and address any anomalous signals that might arise during experimental procedures.

What factors should be considered when optimizing ELISA protocols with SPBPB21E7.05 antibody?

Optimizing ELISA protocols with the SPBPB21E7.05 antibody requires careful consideration of multiple parameters to achieve maximum sensitivity and specificity. Antibody concentration is a critical factor - researchers should perform titration experiments (typically starting with 1:500 to 1:5000 dilutions) to determine the optimal working concentration that provides maximum specific signal with minimal background . Blocking buffer composition significantly impacts assay performance; testing different blocking agents (BSA, casein, non-fat dry milk) at various concentrations (1-5%) can help minimize non-specific binding while preserving specific antigen recognition . Incubation conditions including temperature (4°C, room temperature, or 37°C) and duration (1 hour to overnight) should be systematically optimized as these parameters affect binding kinetics and assay sensitivity . Sample preparation methods must be standardized, ensuring consistent protein extraction and quantification from S. pombe samples to enable reliable comparison between experimental conditions . Additionally, washing stringency (buffer composition, number of washes) significantly impacts signal-to-noise ratio and should be optimized for each specific application . Implementing a standard curve using purified SPBPB21E7.05 protein at known concentrations allows for accurate quantification of unknown samples.

How can researchers verify the specificity of SPBPB21E7.05 antibody in their experimental system?

Verifying the specificity of the SPBPB21E7.05 antibody in experimental systems requires a multi-faceted approach combining complementary validation techniques. Researchers should perform peptide competition assays where the antibody is pre-incubated with excess immunizing peptide before application in the experimental system; disappearance of signal confirms specificity to the target epitope, similar to the method described for ApoL1 antibody validation . Genetic approaches provide powerful validation by comparing signal between wild-type S. pombe and strains with SPBPB21E7.05 gene knockout, deletion, or RNAi-mediated knockdown; absence or reduction of signal in modified strains confirms antibody specificity . Immunoprecipitation followed by mass spectrometry analysis can identify all proteins captured by the antibody, revealing potential cross-reactivity with unintended targets . Orthogonal detection methods employing alternative antibodies targeting different epitopes of the same protein, or using tagged protein expression systems, can provide concordance testing to strengthen confidence in antibody specificity . Additionally, specificity can be assessed across different sample types (cell lysates, subcellular fractions) to ensure consistent target recognition across experimental conditions . These comprehensive validation approaches collectively provide robust evidence for antibody specificity before proceeding with complex experimental applications.

How can SPBPB21E7.05 antibody be utilized in studying protein-protein interactions in S. pombe?

The SPBPB21E7.05 antibody offers sophisticated approaches for investigating protein-protein interactions involving the target protein in S. pombe. Co-immunoprecipitation (co-IP) represents a primary application, where the antibody can be used to capture SPBPB21E7.05 protein complexes from cellular lysates under native conditions, followed by identification of interacting partners through Western blotting or mass spectrometry . Proximity ligation assays (PLA) provide an advanced in situ technique where the SPBPB21E7.05 antibody is used in conjunction with antibodies against suspected interaction partners; positive signals occur only when proteins are in close proximity (<40 nm), enabling visualization of interactions within cellular compartments . For pull-down validation studies, the antibody can be used in reciprocal immunoprecipitation experiments where potential interacting partners identified in initial screens are immunoprecipitated and probed for SPBPB21E7.05 co-precipitation . ChIP-seq applications may be possible if SPBPB21E7.05 has DNA-binding properties or associates with chromatin, allowing researchers to map genomic binding sites of the protein complex . When designing these interaction studies, researchers should consider using crosslinking agents of various lengths to capture both stable and transient interactions, and employ appropriate buffer conditions to maintain native protein conformations while minimizing non-specific interactions.

What approaches can be used to investigate post-translational modifications of SPBPB21E7.05 protein using this antibody?

Investigating post-translational modifications (PTMs) of SPBPB21E7.05 protein requires strategic implementation of complementary techniques leveraging the specificity of the antibody. Researchers can employ immunoprecipitation with the SPBPB21E7.05 antibody followed by Western blotting with modification-specific antibodies (phospho-, ubiquitin-, SUMO-, acetyl-specific) to detect the presence of specific PTMs on the isolated protein . Mass spectrometry analysis of immunoprecipitated SPBPB21E7.05 provides a comprehensive approach for identifying and mapping multiple PTMs simultaneously, revealing modification sites and their relative abundances . Two-dimensional gel electrophoresis followed by Western blotting can separate protein isoforms based on charge differences introduced by PTMs, enabling visualization of the PTM landscape of the protein . For temporal studies of dynamic modifications, researchers can combine the SPBPB21E7.05 antibody with PTM-specific antibodies in time-course experiments following cellular stimulation or stress conditions . When designing PTM studies, consideration should be given to preserving modifications during sample preparation by including appropriate phosphatase inhibitors, deubiquitinase inhibitors, or other PTM-preserving agents in lysis buffers . Additionally, researchers should note that the epitope recognized by the SPBPB21E7.05 antibody might itself be subject to modifications that could affect antibody binding, potentially necessitating the use of multiple antibodies recognizing different regions of the protein.

How can the SPBPB21E7.05 antibody be adapted for super-resolution microscopy applications?

Adapting the SPBPB21E7.05 antibody for super-resolution microscopy requires specific modifications and optimization strategies to achieve high-quality imaging data. Researchers should consider direct fluorophore conjugation of the purified antibody using amine-reactive dyes compatible with super-resolution techniques (e.g., Alexa Fluor 647 for STORM, ATTO 488 for STED), which reduces the signal-to-noise ratio by eliminating the need for secondary antibodies . For optimal labeling density critical in techniques like PALM and STORM, titration experiments should determine the appropriate antibody concentration that balances between sufficient signal and minimized background, typically using lower concentrations (1:1000-1:5000) than standard immunofluorescence . Sample preparation protocols require significant optimization, including fixation methods (e.g., 4% PFA versus methanol) and permeabilization conditions that preserve both epitope accessibility and cellular ultrastructure . When designing multi-color super-resolution experiments, careful selection of fluorophores with minimal spectral overlap and appropriate controls for chromatic aberration correction are essential . For quantitative super-resolution applications, researchers should implement clustering analysis algorithms to extract meaningful biological information about SPBPB21E7.05 spatial organization and develop standardized workflows for image processing that include drift correction, localization precision determination, and resolution estimation . Additionally, correlation with electron microscopy through techniques like CLEM (Correlative Light and Electron Microscopy) can provide contextual ultrastructural information about the labeled SPBPB21E7.05 protein.

What are the most common causes of weak or absent signal when using SPBPB21E7.05 antibody, and how can they be addressed?

When encountering weak or absent signals with the SPBPB21E7.05 antibody, researchers should systematically evaluate several potential causes and implement corresponding solutions. Insufficient target protein expression represents a common issue; researchers should verify SPBPB21E7.05 expression levels in their specific S. pombe strain and growth conditions using RT-qPCR before proceeding with protein detection methods . Antibody degradation may occur due to improper storage or handling; storing aliquots at recommended temperatures (-20°C or -80°C), avoiding repeated freeze-thaw cycles, and checking antibody functionality using a known positive control sample can address this issue . Inadequate protein extraction or transfer efficiency in Western blotting applications can be improved by optimizing lysis buffer composition (considering detergent types and concentrations), extending transfer times, or using alternative transfer methods (semi-dry versus wet transfer) . For detection sensitivity issues, signal amplification strategies can be implemented, including using more sensitive detection substrates (enhanced chemiluminescence or near-infrared fluorescent systems), increasing antibody concentration within recommended ranges, or employing biotin-streptavidin amplification systems . If epitope masking is suspected due to protein folding or complex formation, adjusting denaturation conditions (increasing SDS concentration, adding reducing agents, or heat treatment duration) can improve epitope accessibility . Additionally, researchers should consider that post-translational modifications might affect epitope recognition; treating samples with appropriate enzymes (phosphatases, deglycosylases) prior to analysis can help determine if modifications are interfering with antibody binding .

How can researchers minimize background and non-specific binding when using SPBPB21E7.05 antibody?

Minimizing background and non-specific binding when using the SPBPB21E7.05 antibody requires implementation of multiple optimized strategies across experimental protocols. Blocking optimization is fundamental; researchers should systematically test different blocking agents (BSA, casein, non-fat dry milk, commercial blocking solutions) at various concentrations (1-5%) and incubation times (30 minutes to overnight) to identify the optimal combination that reduces background while preserving specific signal . Antibody dilution optimization through careful titration experiments helps identify the minimum effective concentration that maintains specific signal while reducing non-specific binding; starting with manufacturer recommendations and testing 2-fold serial dilutions above and below is a practical approach . Washing protocol modifications significantly impact background reduction; increasing wash duration, frequency (5-6 washes instead of 3), and using higher detergent concentrations (0.1-0.5% Tween-20) in wash buffers can effectively remove unbound antibodies . For Western blotting applications, membrane pre-adsorption with irrelevant proteins or pre-incubation of antibody with control lysates (from organisms lacking the target) can sequester antibodies with non-specific affinities . Buffer composition adjustments including addition of carrier proteins (0.1-0.5% BSA), non-ionic detergents, or salt concentration modifications (150-500 mM NaCl) can significantly reduce non-specific hydrophobic and ionic interactions . Additionally, implementing a secondary antibody-only control in parallel enables researchers to distinguish between background caused by primary versus secondary antibody binding, informing targeted optimization strategies for each component of the detection system .

How does the performance of polyclonal SPBPB21E7.05 antibody compare with monoclonal antibodies in research applications?

The polyclonal nature of the SPBPB21E7.05 antibody offers distinct performance characteristics compared to monoclonal alternatives that researchers should consider when designing experiments. Polyclonal antibodies like SPBPB21E7.05 recognize multiple epitopes on the target protein, providing higher detection sensitivity particularly useful for low-abundance proteins, but potentially increasing the risk of cross-reactivity with structurally similar proteins . In contrast, monoclonal antibodies offer superior specificity for a single epitope but may fail to detect the target if that epitope is masked by protein folding, denaturation conditions, or post-translational modifications . For applications requiring robust detection across varying experimental conditions, the polyclonal SPBPB21E7.05 antibody provides resilience to epitope alteration through its recognition of multiple binding sites, while monoclonal antibodies offer more consistent lot-to-lot reproducibility for longitudinal studies . When considering immunoprecipitation applications, polyclonal antibodies typically capture more target protein through avidity effects (binding through multiple epitopes simultaneously), whereas monoclonal antibodies offer cleaner precipitates with fewer non-specific interactions . For quantitative applications, researchers should develop standard curves using both antibody types as the broader epitope recognition of polyclonal antibodies can sometimes yield different concentration estimates compared to monoclonal antibodies . The table below summarizes key performance differences:

What considerations are important when analyzing SPBPB21E7.05 protein expression data across different experimental conditions?

When analyzing SPBPB21E7.05 protein expression data across different experimental conditions, researchers must implement rigorous normalization and statistical approaches to ensure valid comparisons. Loading control selection is critical; researchers should use established S. pombe housekeeping proteins (e.g., α-tubulin, GAPDH) or total protein staining methods (Ponceau S, SYPRO Ruby) that remain stable across the experimental conditions being tested, and validate their stability under the specific conditions of the study . Quantification methodology significantly impacts results; researchers should employ digital image analysis software with appropriate background subtraction methods, avoid saturated signals that exceed the linear detection range, and maintain consistent exposure settings across comparative blots . Biological and technical replication is essential; a minimum of three biological replicates with at least two technical replicates each provides statistical power to detect meaningful differences while accounting for natural biological variation and methodological inconsistencies . Time-course dynamics should be considered when studying SPBPB21E7.05 expression patterns; sampling at multiple time points can reveal transient expression changes that might be missed in single time-point analyses . For multi-condition experiments, researchers should implement robust statistical methods including normality testing, appropriate parametric or non-parametric comparative tests (ANOVA, Kruskal-Wallis), and post-hoc analyses with corrections for multiple comparisons (Tukey, Bonferroni) . Additionally, correlation with orthogonal measurements such as mRNA levels via RT-qPCR provides a comprehensive view of gene expression regulation, potentially revealing post-transcriptional control mechanisms affecting SPBPB21E7.05 protein levels . When publishing, researchers should report complete methodological details including antibody dilutions, exposure times, image processing parameters, and raw quantification data to ensure reproducibility.

How can researchers integrate SPBPB21E7.05 antibody-based findings with other systems biology approaches?

Integrating SPBPB21E7.05 antibody-based findings with systems biology approaches requires strategic implementation of complementary technologies and computational methods to build comprehensive biological insights. Researchers should combine antibody-detected protein abundance data with transcriptomics (RNA-seq) to identify correlation or divergence between mRNA and protein levels, potentially revealing post-transcriptional regulation mechanisms controlling SPBPB21E7.05 expression . Integration with interactome data generated through techniques like proximity labeling (BioID, APEX) or affinity purification-mass spectrometry enables construction of functional protein networks, providing context for SPBPB21E7.05's cellular role . For mechanistic insights, researchers can correlate antibody-detected localization or expression patterns with phenotypic data from high-content imaging or growth assays under various genetic or environmental perturbations . Multi-omics data integration requires sophisticated computational approaches; researchers should employ pathway enrichment analysis, protein-protein interaction networks, and Bayesian network modeling to identify relationships between SPBPB21E7.05 and broader cellular systems . For temporal studies, time-series experiments using the antibody can be integrated with mathematical modeling to predict dynamic behavior of the associated biological processes . Machine learning approaches like those described for antibody-antigen binding prediction can be adapted to analyze complex relationships between SPBPB21E7.05 expression patterns and cellular phenotypes or environmental responses . When designing integrated systems biology studies, researchers should consider databases like PLAbDab, which contains approximately 150,000 antibody sequences with rich metadata, providing valuable comparative information for broader contextual understanding of antibody-based research findings .

How might advanced antibody engineering techniques be applied to enhance SPBPB21E7.05 antibody functionality for specialized applications?

Advanced antibody engineering techniques offer significant potential for enhancing SPBPB21E7.05 antibody functionality beyond its current capabilities. Researchers could employ computational antibody design tools similar to AbDesigner to identify optimal epitopes with enhanced immunogenicity while maintaining specificity, potentially improving signal strength in detection applications . Fragment-based engineering approaches could generate Fab or scFv derivatives of the SPBPB21E7.05 antibody with smaller size and improved tissue penetration properties for applications requiring access to restricted cellular compartments . Site-specific conjugation technologies using unnatural amino acid incorporation or enzymatic modification could enable precise attachment of fluorophores, biotin, or other functional groups at defined positions, minimizing interference with antigen binding while maximizing labeling efficiency . For live-cell applications, researchers might develop membrane-permeable nanobody derivatives based on the SPBPB21E7.05 binding regions, allowing real-time monitoring of target protein dynamics in living S. pombe cells . Bivalent antibody engineering strategies combining SPBPB21E7.05 specificity with complementary antibodies against interaction partners could enable selective detection of specific protein complexes . Affinity maturation through directed evolution approaches including phage display or yeast surface display could generate variants with substantially improved binding properties, potentially enabling detection of lower abundance SPBPB21E7.05 protein . For therapeutic research applications, chimerization with human constant regions could reduce immunogenicity while maintaining the specificity of the original rabbit-derived antibody . Implementing these engineering strategies would require specialized protein engineering expertise but could significantly expand the research applications of SPBPB21E7.05 antibodies beyond their current capabilities.

What emerging technologies could complement SPBPB21E7.05 antibody-based research for comprehensive protein characterization?

Emerging technologies offer powerful complementary approaches to SPBPB21E7.05 antibody-based research, enabling more comprehensive protein characterization. Single-cell proteomics techniques like mass cytometry (CyTOF) or microfluidic-based single-cell Western blotting could be combined with SPBPB21E7.05 antibody detection to reveal cell-to-cell heterogeneity in protein expression that might be masked in population-average measurements . Advanced imaging technologies including lattice light-sheet microscopy or expansion microscopy paired with SPBPB21E7.05 antibody labeling could provide unprecedented spatiotemporal resolution of protein localization and dynamics with minimal photobleaching and phototoxicity . Proximity labeling methods such as TurboID or APEX2 fused to protein partners of SPBPB21E7.05 could map the local interactome in native cellular contexts, revealing transient or weak interactions that might be missed in traditional co-immunoprecipitation approaches . For structural characterization, cryo-electron tomography of immunogold-labeled samples using SPBPB21E7.05 antibodies could visualize the target protein within its native cellular ultrastructure at near-atomic resolution . Machine learning approaches for antibody-antigen binding prediction could optimize experimental design by predicting cross-reactivity or identifying optimal conditions for SPBPB21E7.05 antibody performance . Active learning strategies, as described for antibody-antigen binding prediction, could reduce the experimental burden by intelligently selecting the most informative experiments to characterize SPBPB21E7.05 protein under various conditions . Microfluidic antibody-based sensors could enable real-time monitoring of SPBPB21E7.05 expression or secretion in live cell cultures, providing dynamic information about protein regulation . Integration of these emerging technologies with traditional antibody-based methods would provide multi-dimensional characterization of SPBPB21E7.05 protein that no single approach could achieve alone.